As of this Thursday, the CDC is updating COVID-19 case and death data every week instead of every day. Here are some thoughts on interpreting COVID-19 data in the wake of this change, citing an article I recently wrote for The Atlantic.
This week, the CDC announced a big change to its COVID-19 data reporting: instead of updating case and death numbers daily, the figures will be updated weekly. The change comes into effect on October 20.
On September 2, 2022, the federal government stopped taking orders for free at-home COVID-19 tests. The day this program ended, I sent a public records request to the federal government asking for data on how many tests were distributed. I just received some data back from my request; here’s what the numbers show.
Last Sunday, 60 Minutes aired an interview with President Joe Biden in which he declared the pandemic is “over,” noting that everyone at the Detroit Auto Show “seems to be in pretty good shape.” But there are millions of Americans Biden wasn’t seeing: people who aren’t in good shape.
COVID-19 is still a public health emergency. At the moment, this is true according to both the general definition of this term and official declarations by the federal government. But the latter could change in the coming months, likely leading to more fragmentation in U.S. COVID-19 data.
The COVID-19 Data Dispatch is going on hiatus for the month of August 2022. Here are some tips for keeping track of COVID-19 numbers while we’re on this break, and a bit of context about why we’re taking four weeks off.
Last week, I had a new story published at FiveThirtyEight about the challenges a new CDC forecasting center is facing. Here’s one of the interviews I did for that piece, with epidemiologist Jason Salemi.
Last week, I shared a new page from the Department of Health and Human Services (HHS), reporting statistics on COVID-19 therapeutic distribution in the U.S. The new dataset is a helpful step, but it falls far short of the information we actually need to examine who has access to COVID-19 treatments (particularly Paxlovid) and address potential health equity issues.